Company / Current Assets
Myriad Genetics, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$332.6M
FY2025
5-year range
$274.6M / $484.8M
FY2021-FY2025
Trend
+11.6%
vs FY2024
Sector context
#153 of 213
Health Care
What the data says
At $333M, Myriad Genetics, Inc.'s current assets ranks #153 of 213 in the Health Care sector. Current Assets has fluctuated over the past 10 years, ranging from $275M in FY2022 to $485M in FY2021.
Based on SEC 10-K filings.
$333M in FY2025 with a 5-year CAGR of -3.1%.
Improved from $314M to $333M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +6.6%
- 5-Year CAGR
- -3.1%
- 10-Year CAGR
- -
Sector benchmark
#153 of 213 in Health CareTop 72% of 213This company $332.6M Sector average $2.5B
▼
-86.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.1%, indicating a declining trend.
- In FY2025, current assets increased 11.6% year-over-year.
- Ranks #153 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $332.6M | +11.6% |
| FY2024 | $298.0M | -5.0% |
| FY2023 | $313.6M | +14.2% |
| FY2022 | $274.6M | -43.4% |
| FY2021 | $484.8M | +24.5% |
| FY2020 | $389.4M | +11.7% |
| FY2019 | $348.6M | +6.4% |
| FY2018 | $327.6M | +8.6% |
| FY2017 | $301.7M | -4.1% |
| FY2016 | $314.5M | +10.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026